These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27711199)

  • 21. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
    Moses RG; Round E; Shentu Y; Golm GT; O'neill EA; Gantz I; Engel SS; Kaufman KD; Goldstein BJ
    J Diabetes; 2016 Sep; 8(5):701-11. PubMed ID: 26625270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
    Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
    JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
    Umayahara R; Yonemoto T; Kyou C; Morishita K; Ogawa T; Taguchi Y; Inoue T
    Endocr J; 2014; 61(12):1163-70. PubMed ID: 25168659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
    Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.
    Sharma M; Beckley N; Nazareth I; Petersen I
    BMJ Open; 2017 Oct; 7(10):e017260. PubMed ID: 29084794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus.
    Shankar RR; Xu L; Golm GT; O'Neill EA; Goldstein BJ; Kaufman KD; Engel SS
    Int J Clin Pract; 2015 Jun; 69(6):626-31. PubMed ID: 25652751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes.
    Shankar RR; Zeitler P; Deeb A; Jalaludin MY; Garcia R; Newfield RS; Samoilova Y; Rosario CA; Shehadeh N; Saha CK; Zhang Y; Zilli M; Scherer LW; Lam RLH; Golm GT; Engel SS; Kaufman KD
    Pediatr Diabetes; 2022 Mar; 23(2):173-182. PubMed ID: 34779087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
    Schernthaner G; Lavalle-González FJ; Davidson JA; Jodon H; Vijapurkar U; Qiu R; Canovatchel W
    Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
    Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
    Expert Opin Pharmacother; 2017 Aug; 18(12):1179-1186. PubMed ID: 28714741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin.
    Pareek A; Chandurkar NB; Salkar HR; Borkar MS; Tiwari D
    Am J Ther; 2013 Jan; 20(1):41-7. PubMed ID: 21326082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
    Kobayashi K; Yokoh H; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K;
    Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and safety of initial treatment with glimpeiride versus sitagliptin in type 2 diabetes].
    Tamez-Pérez HE;
    Rev Med Inst Mex Seguro Soc; 2015; 53(2):142-8. PubMed ID: 25760742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
    Garvey WT; Van Gaal L; Leiter LA; Vijapurkar U; List J; Cuddihy R; Ren J; Davies MJ
    Metabolism; 2018 Aug; 85():32-37. PubMed ID: 29452178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
    Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
    Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T; Stirban A; Terjung A; Esmaeili H; Berk A; Thiemann S; Chilton R; von Eynatten M; Marx N
    Cardiovasc Diabetol; 2017 Jan; 16(1):13. PubMed ID: 28109295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
    Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
    Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.
    Ji L; Han P; Wang X; Liu J; Zheng S; Jou YM; O'Neill EA; Golm GT; Engel SS; Kaufman KD; Shankar RR
    J Diabetes Investig; 2016 Sep; 7(5):727-36. PubMed ID: 27181998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.
    Kato H; Nagai Y; Ohta A; Tenjin A; Nakamura Y; Tsukiyama H; Sasaki Y; Fukuda H; Ohshige T; Terashima Y; Sada Y; Kondo A; Sasaoka T; Tanaka Y
    Diabetes Res Clin Pract; 2015 Jul; 109(1):199-205. PubMed ID: 25934525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.